Sunesis Pharmaceuticals

Published: 9-Feb-2002


Sunesis Pharmaceuticals has been granted a US patent (No. 6,335,155) covering its pharmaceutical lead discovery technology, known as tethering. Sunesis is focusing on well-validated disease intervention pathways where conventional discovery approaches have not been successful. The patent claims cover methods for discovering binding elements, called 'monophores', that are selected by a biological target and then can be rapidly identified by mass spectrometry. The methods allow for rapid screening of libraries of monophores to identify initial lead compounds against biological targets.

You may also like